RetaMaps

UT Southwestern Endocrinology — Felona Gunawan, MD

Parkland Memorial Hospital / UT Southwestern · 5200 Harry Hines Blvd · Dallas, TX 75235

2.4· 15 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • Endocrine / metabolic care

About this practice

UT Southwestern Medical Center endocrinology is an academic health-system practice in Dallas. The official faculty profile describes type 1 and type 2 diabetes, general endocrinology, and research in diabetes and obesity, with new-patient and virtual-visit scheduling. Listed sites include Parkland Memorial Hospital (5200 Harry Hines Blvd) and the main UTSW campus (5323 Harry Hines Blvd). This is hospital/academic endocrine care; official pages do not name GLP-1 medications.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsYes
Cash pay acceptedYes
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 2.4
Google rating · 15 reviews
3
reviews in the past year (avg ★ 2.3)

Counts computed by RetaMaps from public Google reviews; most recent review 2026-08-19. Read the reviews themselves on the practice's Google listing.

Clinicians

  • Felona Gunawan, MD

Nearby providers in Dallas

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs